 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- Performance of a Chromogenic Factor IX Activity Assay in the Recovery of Factor IX Replacement Therapies (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_2148;
The mean FIX recovery was 96, 116, 93, 82, 117 and 102% respectively, relative to the theoretical target across all tested levels. There was an over-recovery of Idelvion (albumin fusion recombinant FIX) with a mean recovery of 153%.